DOI: 10.1055/s-00000025

Hormone and Metabolic Research

References

Rizvi NA, Mazieres J, Planchard D. et al.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial.

Lancet Oncol 2015;
16: 257-265

Download Bibliographical Data

Access:
Access:
Access: